CORC  > 中国医学科学院 北京协和医学院
Phase II study of antiangiogenic tyrosine kinase inhibitor apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative advanced breast cancer
Zhu, A.; Yuan, P.; Wang, J.; Fan, Y.; Luo, Y.; Cai, R.; Zhang, P.; Li, Q.; Ma, F.; Xu, B.
2019
卷号79期号:4
ISSN号0008-5472
DOI10.1158/1538-7445.SABCS18-P2-10-01
URL标识查看原文
收录类别SCIE
内容类型期刊论文
URI标识http://www.corc.org.cn/handle/1471x/6337475
专题中国医学科学院 北京协和医学院
推荐引用方式
GB/T 7714
Zhu, A.,Yuan, P.,Wang, J.,et al. Phase II study of antiangiogenic tyrosine kinase inhibitor apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative advanced breast cancer[J],2019,79(4).
APA Zhu, A..,Yuan, P..,Wang, J..,Fan, Y..,Luo, Y..,...&Xu, B..(2019).Phase II study of antiangiogenic tyrosine kinase inhibitor apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative advanced breast cancer.,79(4).
MLA Zhu, A.,et al."Phase II study of antiangiogenic tyrosine kinase inhibitor apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative advanced breast cancer".79.4(2019).
个性服务
查看访问统计
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。


©版权所有 ©2017 CSpace - Powered by CSpace